Emerging CSF and Serum Biomarkers in Multiple Sclerosis

Johanna Oechtering; Sabine Anna Schaedelin; Aleksandra Maleska Maceski; Kerstin Stein; Nafiye Genc; Maximilian Einsiedler; Pascal Benkert; Eline Willemse; Tobias J. Derfuss; Bettina Fischer-Barnicol; Marcus D'Souza; Axel Regeniter; Wayne Hu; Ferhan Qureshi; Sebastian Finkener; Stefanie Mueller; Robert Hoepner; Patrice H. Lalive; Caroline Pot; C Gobbi; C Zecca; P. Roth; Heinz Wiendl; Jan D. Lünemann; Ludwig Kappos; Cristina Granziera; David Leppert; Jens Kuhle; as the Swiss MS Cohort Study; Johanna Oechtering; Sabine Anna Schaedelin

doi:10.1212/nxi.0000000000200578

Key Points

To identify CSF and serum biomarkers that can predict relapse activity and disease severity in multiple sclerosis.
Assessment of biomarkers in cerebrospinal fluid (CSF) and serum samples.
Evaluation of CXCL13, CXCL9, IL-12b in CSF and GFAP, MOG in serum as predictors.
CSF CXCL13, CXCL9, and IL-12b are promising for predicting relapse activity.
Serum GFAP and MOG consistently indicate disease severity.

Implication

Identifies biomarkers for predicting relapse activity and disease severity in multiple sclerosis, indicating potential for improved monitoring.

Abstract

CSF CXCL13, CXCL9, and IL-12b are promising biomarkers for predicting relapse activity, while serum GFAP and MOG appear to be consistent candidates for prognosticating disease severity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oechtering et al. (2026) studied this question.

synapsesocial.com/papers/69edab814a46254e215b3826 https://doi.org/10.1212/nxi.0000000000200578

View Full Paper

Ask AI

Bookmark

Share

Emerging CSF and Serum Biomarkers in Multiple Sclerosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Emerging CSF and Serum Biomarkers in Multiple Sclerosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading